Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinaseBALLARD, Peter; BARLAAM, Bernard C; PEARSON, Stuart E et al.Bioorganic & medicinal chemistry letters (Print). 2007, Vol 17, Num 22, pp 6326-6329, issn 0960-894X, 4 p.Article

A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinaseBARLAAM, Bernard; BALLARD, Peter; OGILVIE, Donald J et al.Bioorganic & medicinal chemistry letters (Print). 2008, Vol 18, Num 2, pp 674-678, issn 0960-894X, 5 p.Article

Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitorsDUCRAY, Richard; BALLARD, Peter; BARLAAM, Bernard C et al.Bioorganic & medicinal chemistry letters (Print). 2008, Vol 18, Num 3, pp 959-962, issn 0960-894X, 4 p.Article

5-substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinaseBALLARD, Peter; BRADBURY, Robert H; HENNEQUIN, Laurent F. A et al.Bioorganic & medicinal chemistry letters (Print). 2005, Vol 15, Num 19, pp 4226-4229, issn 0960-894X, 4 p.Article

Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinaseBARLAAM, Bernard; ACTON, David G; OGILVIE, Donald J et al.Bioorganic & medicinal chemistry letters (Print). 2008, Vol 18, Num 6, pp 1799-1803, issn 0960-894X, 5 p.Article

Inhibitors of epidermal growth factor receptor tyrosine kinase : Optimisation of potency and in vivo pharmacokineticsBALLARD, Peter; BRADBURY, Robert H; WILLIAMS, Emma J et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 18, pp 4908-4912, issn 0960-894X, 5 p.Article

AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerWEDGE, Stephen R; KENDREW, Jane; CHESTER, Rosemary et al.Cancer research (Baltimore). 2005, Vol 65, Num 10, pp 4389-4400, issn 0008-5472, 12 p.Article

Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapiesKENDREW, Jane; ODEDRA, Rajesh; LOGIE, Armelle et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 4, pp 1021-1032, issn 0344-5704, 12 p.Article

Inhibitors of epidermal growth factor receptor tyrosine kinase : Novel C-5 substituted anilinoquinazolines designed to target the ribose pocketBALLARD, Peter; BRADBURY, Robert H; PASS, Martin et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 6, pp 1633-1637, issn 0960-894X, 5 p.Article

Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitorsHENNEQUIN, Laurent F; STOKES, Elaine S. E; THOMAS, Andrew P et al.Journal of medicinal chemistry (Print). 2002, Vol 45, Num 6, pp 1300-1312, issn 0022-2623Article

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationWEDGE, Stephen R; OGILVIE, Donald J; GRAHAM, George A et al.Cancer research (Baltimore). 2002, Vol 62, Num 16, pp 4645-4655, issn 0008-5472Article